-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Asparaginase is a bacterial protein that has been used to treat acute lymphoblastic leukemia (ALL) and lymphocytic lymphoma (LBL) and has high potential for sensitization and immunogenicity
AALL1931 is a Phase 2/3 study conducted in collaboration with the Pediatric Oncology Gene Association to evaluate the efficacy and safety
Replace asparaginase
A total of 167 patients were enrolled: Cohort 1a (n=33), Cohort 1b (n=83), and Cohort 1c (n=51).
The mean SAA levels (IU/mL) for the 72nd hour of Cohort 1a, Cohort 1b, and Cohort 1c were 0.
Grade 3/4 treatment-related adverse events (TRAEs) occurred in 86/167 (51%) patients with TRAEs that led to treatment interruption included pancreatitis (6%), anaphylaxis (5%), elevated alanine aminotransferase (1%), and hyperammonia (1%)
Overall, the findings show that JZP458 (intramuscular injection) of the Monday/Wednesday/Friday 25/25/50 mg/m2 dose regimen is effective in patients with acute lymphoblastic leukemia/lymphoblastic lymphoma, and its safety is consistent
Original Source:
Maese Luke D,Loh Mignon L,Choi Mi Rim et al.